A New Approach to the Treatment of Metastatic Paraganglioma: Sorafenib.
- Author:
Meral GUNALDI
1
;
Ismail Oguz KARA
;
Berna Bozkurt DUMAN
;
Cigdem Usul AFSAR
;
Melek ERGIN
;
Arbil AVCI
Author Information
- Publication Type:Case Report
- Keywords: Extra-adrenal paraganglioma; Neoplasm metastasis; Sorafenib; Pheochromocytomas; Tyrosine kinase inhibitor
- MeSH: Abdomen; Adult; Chromaffin Cells; Consensus; Diagnosis; Drug Therapy; Female; Follow-Up Studies; Headache; Humans; Neoplasm Metastasis; Paraganglioma*; Paraganglioma, Extra-Adrenal; Pheochromocytoma; Plasma; Positron-Emission Tomography; Recurrence; Thorax
- From:Cancer Research and Treatment 2014;46(4):411-414
- CountryRepublic of Korea
- Language:English
- Abstract: Paragangliomas are relatively rare chromaffin cell tumors which may be cured through resection. Patients with paragangliomas may develop metastatic diseases. There is no consensus regarding refractory chemotherapy for treatment of metastatic disease. In this report, we presented a case of a 43-year-old woman who was admitted to the hospital with a history of episodic headaches, diaphoresis, and weakness. Elevated plasma catecholamine levels and a right paraaortic mass were observed on computed tomography. The mass was excised, and a diagnosis of paraganglioma was confirmed. After 20 months of follow-up, local recurrence and metastases were detected in the thorax, abdomen, and skeletal system. Plasma and urinary catecholamine levels were high. Chemotherapy was administered, and no improvement was observed. Therefore, following this palliative conventional chemotherapy, sorafenib was administered for three months, and, finally, positron emission tomography showed that the patient's lesions had completely regressed.
